AIMT shares surge (12% /PM) as PhIII peanut allergy study wows on the primary endpoint, setting up FDA pitch https://endpts.com/aimmune-shares-surge-as-phiii-peanut-allergy-study-scores-on-the-primary-endpoint-setting-up-fda-pitch/ PS—Endpoints has made it very hard to copy/paste blurbs from their site. Have to do it in very small chunks at a time.